


Practitioner's Docket No. PITT-1 DIV



PATENT

RECEIVED
JAN 16 2001

TECH CENTER 1600/2900

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Patent application

of _____
Inventor(s)

for _____
Title of invention

OR

In re application of: Joel S. Greenberger, Paul A. DiMilla, Michael M. Domach,
Raymond K. Houck

Application No.: 0 9 /292,056 Group Art Unit: 1655

Filed: April 14, 1999 Examiner: J. Souaya

For: METHOD AND APPARATUS FOR HOLDING CELLS

Assistant Commissioner for Patents
Washington, D.C. 20231

**TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT
WITHIN THREE MONTHS OF FILING OR
BEFORE MAILING OF FIRST OFFICE ACTION (37 C.F.R. § 1.97(b))**

NOTE: "An information disclosure statement shall be considered by the Office if filed by the applicant: (1) within three months of the filing date of a national application; (2) within three months of the date of entry of the national stage as set forth in § 1.491 in an international application; or (3) before the mailing date of a first Office action on the merits, whichever event occurs last." 37 C.F.R. § 1.97(b).

CERTIFICATE OF MAILING/TRANSMISSION (37 C.F.R. § 1.8(a))

I hereby certify that this correspondence is, on the date shown below, being:

MAILING

☒ deposited with the United States Postal Service with sufficient postage as first class mail, in an envelope addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231.

Date: 1/3/01

FACSIMILE

☐ transmitted by facsimile to the Patent and Trademark Office.

Tracey L. Milka
Signature
Tracey L. Milka
(type or print name of person certifying)

(Transmittal of Information Disclosure Statement Within Three Months of Filing or Before Mailing of First Office Action [6-3]—page 1 of 2)

NOTE: The "filing date of a national application" under 37 C.F.R. § 1.97(b) has two possible meanings. Where the filing is a direct one to the United States Patent & Trademark Office, the filing is defined in 37 C.F.R. § 1.53(b) as "the date on which: (1) A specification containing a description pursuant to § 1.71 and at least one claim pursuant to § 1.75; and (2) any drawing required by § 1.81(a), are filed in the Patent and Trademark Office in the name of the actual inventor or inventors as required by § 1.41." 37 C.F.R. § 1.97(b)(1). On the other hand, an international application that enters the national stage occurs when the applicant has filed the documents and fees required by 35 U.S.C. § 371(c) within the periods set forth in § 1.494 or § 1.495. 35 U.S.C. § 371(c) requires the filing of the following: (1) the basic national fee; (2) a copy of the international application, unless already sent by the International Bureau, and optionally an English translation if filed in another language; and, also optionally (3) amendments under PCT Article 19, with a translation into English if made in another language; (4) an oath or declaration; and (5) a translation into English of any annexes to the international preliminary examination report, if such annexes were made in another language. The optional items must be submitted later, with surcharges. 37 C.F.R. § 1.97(b)(2).

IDENTIFICATION OF TIME OF FILING THE ACCOMPANYING INFORMATION DISCLOSURE STATEMENT

The information disclosure statement submitted herewith is being filed within three months of the filing date of the application or date of entry into the national stage of an international application or before the mailing date of a first Office action on the merits, whichever event occurs last. 37 C.F.R. § 1.97(b).

NOTE: "No certification or fee is due when the filing is made within the above time period. It is advisable to ensure that no Office action has been mailed if the disclosure statement is delayed until after three months from filing."

NOTE: "An information disclosure statement will be considered to have been filed on the day it was received in the Office, or on an earlier date of a mailing if accompanied by a properly executed certificate of mailing under 37 C.F.R. 1.8, or Express Mail certificate under 37 C.F.R. 1.10. An Office action is mailed on the date indicated in the Office action." Notice of April 20, 1992 (1138 O.G. 37-41, 39).

NOTE: "The term 'national application' includes continuing applications (continuations, divisions, continuations-in-part) so three-months will be measured from the actual filing date of an application as opposed [sic] to the effective date of a continuing application." Notice of April 20, 1992 (1138 O.G. 37-41, 39).

NOTE: "An action on the merits means an action which treats the patentability of the claims in an application, as opposed to only formal or procedural requirements. An action on the merits would, for example, contain a rejection or indication of allowability of a claim or claims rather than just a restriction requirements (37 C.F.R. 1.142) or just a requirement for additional fees to have a claim considered (37 C.F.R. 1.16(d)). Thus, if an application was filed on Jan. 1 and the first Office action on the merits was not mailed until six months later on July 1, the examiner would be required to consider any proper information disclosure statement filed prior to July 1." Notice of April 20, 1992 (1138 O.G. 37-41, 39).

WARNING: "A petition for suspension of action to allow applicant time to submit an information disclosure statement will be denied as failing to present good and sufficient reasons, since 37 C.F.R. § 1.97 provides adequate recourse for the timely submission of prior art for consideration by the examiner." Notice of July 6, 1992 (1141 O.G. 63).


SIGNATURE OF PRACTITIONER

Reg. No.: 30,587

Ansel M. Schwartz

Tel. No.: (412) 621-9222

(type or print name of practitioner)


Customer No.:

201 N. Craig Street, Suite 304

P.O. Address

Pittsburgh, PA 15213

(Transmittal of Information Disclosure Statement Within Three Months of Filing or Before Mailing of First Office Action [6-3]—page 2 of 2)



72 of 17-d

[illegible]

)

)

)

)

)

)




RECEIVED
JAN 16 2001

JAN 16 2001
TECH CENTER 1600/2900

CERTIFICATE OF MAILING

I hereby certify that the correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner of Patents and Trademarks, Washington, DC 20231.

RAUCHMARKS, Washington, D.C. 20231.
 (44) ~~XX~~

 Arnold A. Schwartz

Ansel M. Schwartz
Registration No. 30,587

Date

No representation is made or intended that better art than that submitted hereunder is available. Also enclosed is Form PTO-1449A (PTO/SB/08A and PTO/SB/08B).

"Recombinant Human Stem Cell Factor Enhances the Formation of Colonies by CD34⁺ and CD34⁺lin⁻ Cells, and the Generation of Colony-Forming Cell Progeny From CD34⁺lin⁻ Cells Cultured With Interleukin-3, Granulocyte Colony-Stimulating Factor, or Granulocyte-Macrophage Colony-Stimulating Factor"

This is a disclosure regarding recombinant human stem cell factor.

"Evidence that hematopoietic stem cells express mouse *c-kit* but do not depend on steel factor for their generation"

This is a disclosure regarding hematopoietic stem cells.

"Retrovirally Marked CD34-Enriched Peripheral Blood and Bone Marrow Cells Contribute to Long-Term Engraftment After Autologous Transplantation"

This is a disclosure regarding contribution of blood and bone marrow cells to long-term engraftment.

"Enrichment of Human Hematopoietic Stem Cell Activity in the CD34⁺Thy-1⁺Lin⁻ Subpopulation From Mobilized Peripheral Blood"

This is a disclosure regarding enrichment of human hematopoietic stem cell activity in the CD34⁺Thy-1⁺Lin⁻ subpopulation from mobilized peripheral blood.

"Synergistic Effects of Hepatocyte Growth Factor on Human Cord Blood CD34⁺ Progenitor Cells are the Result of c-met Receptor Expression"

This is a disclosure regarding the effects of c-met receptor expressions.

"Direct and synergistic effects of interleukin 11 on murine hemopoiesis in culture"

RECEIVED
JAN 16 2001
TECH CENTER 1600/2900

This is a disclosure regarding the direct and synergistic effects of interleukin 11 on murine hemopoiesis in culture.

"Interleukin 6 enhancement of interleukin 3-dependent proliferation of multipotential hemopoietic progenitors"

This is a disclosure regarding interleukin 6 enhancement of interleukin 3-dependent proliferation of multipotential hemopoietic progenitors.

"Isolation of CD34⁺ Hematopoietic Progenitor Cells by High-Gradient Magnetic Cell Sorting (MACS)"

This is a disclosure regarding the isolation of CD34⁺ hematopoietic progenitor cells by high-gradient magnetic cell sorting.

"Clinical Implications of Positive and Negative Hematopoietic Stem Cell Regulators"

This is a disclosure regarding the clinical implications of positive and negative hematopoietic stem cell regulators.

"Functional characterization of individual human hematopoietic stem cells cultured at limiting dilution on supportive marrow stromal layers"

This is a disclosure regarding the functional characterization of individual human hematopoietic stem cells.

"Cloning and Expression of Unique Murine Macrophage Colony-Stimulating Factor Transcripts"

This is a disclosure regarding the cloning and expression of unique murine macrophage colony-stimulating factor transcripts.

"Long-term repopulation of hematolymphoid cells with only a few hemopoietic stem cells in mice"

This is a disclosure regarding the repopulation of hematolymphoid.

"Expansion in Bioreactors of Human Progenitor Populations from Cord Blood and Mobilized Peripheral Blood"

This is a disclosure regarding human progenitor populations in bioreactors.

"Can Human Hematopoietic Stem Cells Be Cultured Ex Vivo?"

This is a disclosure regarding human hematopoietic cells.

"Evaluation of Ex Vivo Expansion Potential of Cord Blood and Bone Marrow Hematopoietic Progenitor Cells Using Cell Tracking and Limiting Dilution Analysis"

This is a disclosure regarding the potential of cord blood and bone marrow progenitor cells.

"Proliferation of individual hematopoietic progenitors purified from umbilical cord blood"

This is a disclosure regarding the proliferation of individual hematopoietic progenitors purified from umbilical cord blood.

"Murine Hematopoietic Stem and Progenitor Cells:
I. Enrichment and Biologic Characterization"

This is a disclosure regarding hematopoietic stem and progenitor cells.

"Effects of CD34⁺ Cell Selection and Perfusion on
Ex Vivo Expansion of Peripheral Blood Mononuclear Cells"

This is a disclosure regarding the effects of CD34⁺ cell selection and perfusion on ex vivo expansion of peripheral blood mononuclear cells.

"Macrophage Inflammatory Protein 1 α , Interleukin 3 and Diffusible Marrow Stromal Factors Maintain Human Hematopoietic Stem Cells for at least Eight Weeks In Vitro"

This is a disclosure regarding the maintenance of stem cells.

"Retention and Multilineage Expression of Human
Hematopoietic Stem Cells in Human-Sheep Chimeras"

This is a disclosure regarding retention and multilineage expression of human hematopoietic stem cells in human-sheep chimeras.

"Hematopoietic Regulators: Redundancy or Subtlety?"

This is a disclosure regarding hematopoietic regulators.

"Synergistic Interactions Between Interleukin-11 and Interleukin-4
in Support of Proliferation of Primitive Hematopoietic Progenitors of Mice"

This is a disclosure regarding hematopoietic progenitors.

"Rapid and Sustained Hematopoietic Recovery in Lethally Irradiated Mice
Transplanted With Purified Thy-1.¹⁰ Lin⁻ Sca-1⁺ Hematopoietic Stem Cells"

This is a disclosure regarding stem cells.

"Amphotropic Retrovirus Vector Transfer of the v-ras Oncogene to
Human Hematopoietic and Stromal Cells in Continuous Bone Marrow Cultures"

This is a disclosure regarding hematopoietic and stromal cells.

"A Murine Stromal Cell Line Allows the Proliferation of Very Primitive Human
CD34⁺⁺/CD38⁻ Progenitor Cells in Long-Term Cultures and Semisolid Assays"

This is a disclosure regarding a murine stromal cell line.

Direct Comparison by Limiting Dilution Analysis of Long-Term Culture-Initiating Cells in Human Bone Marrow, Umbilical Cord Blood, and Blood Stem Cells"

This is a disclosure regarding direct comparison by limiting dilution analysis of long-term culture-initiating cells in human bone marrow, umbilical cord blood, and blood stem cells.

"Recent Modifications of Technique in Human Long-Term Bone Marrow Cultures"

This is a disclosure regarding bone marrow cultures.

"Long-Term Hematopoietic Cultures"

This is a disclosure regarding long-term hematopoietic cultures.

"Long-Term Generation of Colony-Forming Cells in Liquid Culture of CD34⁺ Cord Blood Cells in the Presence of Recombinant Human Stem Cell Factor"

This is a disclosure regarding the long-term generation of colony-forming cells.

"New Marrow for Old"

This is a disclosure regarding bone marrow transplantation.

"The hematopoietic microenvironment"

This is a disclosure regarding the hematopoietic microenvironment.

"Effects of Substratum Compliance on the Motility, Morphology,
and Proliferation of Adherent Human Glioblastoma Cells"

This is a disclosure regarding glioblastoma cells.

Inside Surgery, "Organ and Tissue Transplant Update"

This is a disclosure regarding information about an update on organ and tissue transplants.

"Receptor-Mediated Adhesive Interactions at the
Cytoskeleton/Substratum Interface During Cell Migration"

This is a disclosure regarding cell migration.

"Measurement of Cell Adhesion and Migration on Protein-Coated Surfaces"

This is a disclosure regarding cell adhesion and migration.

"Measurement of Individual Cell Migration Parameters for Human Tissue Cells"

This is a disclosure regarding the measurement of individual cell migration parameters for human tissue cells.

"Maximal Migration of Human Smooth Muscle Cells on Fibronectin
and Type IV Collagen Occurs at an Intermediate Attachment Strength"

This is a disclosure regarding migration of muscle cells.

"Effects of Hepatocyte Growth Factor and IL-11 on
Human Cord Blood CD34+ Progenitor Cells"

This is a disclosure regarding the effects of hepatocyte growth factor.

"Synergistic Effects of Hepatocyte Growth Factor on In Vitro
Generation of CFU-GM From Human Cord Blood CD34+ Progenitor Cells"

This is a disclosure regarding synergistic effects of hepatocyte growth factor.

CERTIFICATE OF MAILING

I hereby certify that the correspondence is
being deposited with the United States Postal
Service as first class mail in an envelope
addressed to: Commissioner of Patents and
Trademarks, Washington, DC 20529,
on 1/3/01




Ansel M. Schwartz
Registration No. 30,587

1/3/01
Date

Respectfully submitted,

JOEL S. GREENBERGER, ET AL.

By 

Ansel M. Schwartz, Esquire
Reg. No. 30,587
One Sterling Plaza
201 N. Craig Street
Suite 304
Pittsburgh, PA 15213
(412) 621-9222

Attorney for Applicants

